To evaluate the effect of adjuvant radiotherapy (RT) after breast conservation surgery in different breast cancer subtypes in a large, randomized clinical trial with long-term follow-up.
To evaluate the effect of adjuvant radiotherapy (RT) after breast conservation surgery in different breast cancer subtypes in a large, randomized clinical trial with long-term follow-up.
Patients and Methods
Tumor tissue was collected from 1,003 patients with node-negative, stage I and II breast cancer who were randomly assigned in the Swedish Breast Cancer Group 91 Radiotherapy trial between 1991 and 1997 to breast conservation surgery with or without RT. Systemic adjuvant treatment was sparsely used (8%). Subtyping was performed with immunohistochemistry and in situ hybridization on tissue microarrays for 958 tumors.
Results
RT reduced the cumulative incidence of ipsilateral breast tumor recurrence (IBTR) as a first event within 10 years for luminal A-like tumors (19% v 9%; P = .001), luminal B-like tumors (24% v 8%; P , .001), and triple-negative tumors (21% v 6%; P = .08), but not for human epidermal growth factor receptor 2-positive (luminal and nonluminal) tumors (15% v 19%; P = .6); however, evidence of an overall difference in RT effect between subtypes was weak (P = .21). RT reduced the rate of death from breast cancer (BCD) for triple-negative tumors (hazard ratio, 0.35; P = .06), but not for other subtypes. Death from any cause was not improved by RT in any subtype. A hypothesized clinical low-risk group did not have a low risk of IBTR without RT, and RT reduced the rate of IBTR as a first event after 10 years (20% v 6%; P = .008), but had no effect on BCD or death from any cause.
INTRODUCTION
The majority of patients with early breast cancer undergo breast conservation surgery (BCS), and the combination with adjuvant whole-breast radiation therapy (RT) is a safe alternative to mastectomy in these cases. 1,2 The addition of RT primarily prevents ipsilateral breast tumor recurrences (IBTRs), but also reduces breast cancer deaths (BCDs), as demonstrated in meta-analyses by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG), where one BCD was prevented at 15 years for every four recurrences avoided by year 10 3 ; however, the meta-analysis also suggests that approximately 70% of node-negative patients will suffer an IBTR within 10 years with surgery alone, whereas approximately 10% suffer an IBTR despite RT, thus implying overtreatment and undertreatment of patients. 2a,3 No predictive test is available today and traditional histopathology and immunohistochemistry (IHC) markers have demonstrated that RT reduces the rate of IBTR in all patient groups, although a larger, but not significantly different, effect is observed in tumors that express the estrogen receptor (ER). 3, 4 Furthermore, numerous attempts have been made to define a low-risk group of older patients who could be spared RT, for example, patients with small, lowgrade, lymph node-negative (N0) and ER-positive tumors. The results are not conclusive as most studies compare endocrine treatment to endocrine treatment plus RT and find a good effect from RT also in this patient group.
5-13
On a molecular level, gene expression tests can reveal the intrinsic subtype of the tumor and are prognostic of loco-regional and distant recurrence, as well as for the absolute effect of adjuvant systemic therapy.
14-16 Attempts have been made to create gene expression-based classifiers that are specific for response to RT, but these have proven hard to validate in independent data sets, and no prospective trials have been presented. [17] [18] [19] [20] [21] [22] [23] [24] A cost-effective surrogate method for determining intrinsic subtypes on the basis of high-quality, centralized IHC has been proposed with criteria set up by the St Gallen International Breast Cancer Conference (2013) Expert Panel. 25 Surrogate subtypes have been associated with the risk of local recurrence after BCS in patients treated with RT and adjuvant systemic therapy.
26-29
Recently, Liu et al 5 evaluated the response to RT in different subtypes and found that, although not statistically significant, highrisk tumors (human epidermal growth factor receptor 2 (HER2) positive, basal-like or triple negative) have the greatest benefit from RT and that a clinical low-risk, luminal A-like group of tumors has no benefit from RT. Our group recently published the long-term results of the Swedish Breast Cancer Group 91 Radiotherapy (SweBCG91-RT) randomized trial and found that, by using clinicopathologic variables and ER status, no group could be spared RT, although with a higher, but not significantly different effect in ER-positive tumors. 13 Thus, the literature is discordant on how different breast cancer subtypes respond to RT, and most prior studies have investigated the risk of recurrence after RT, but not the effect of RT. The aim of the current study was to use centralized, high-quality pathology evaluations to subtype tumors from the SweBCG91-RT study and evaluate the treatment-predictive effect of subtypes for RT in this large, randomized clinical trial with long-term follow-up and sparse use of adjuvant systemic therapy.
10,13

PATIENTS AND METHODS
Patients and Study Design
Patients were from the SweBCG91-RT trial, which has been reported previously.
10,13,30,31 Study details are found in the original publications. In brief, patients with N0, stage I and IIA breast cancer were randomly assigned between 1991 and 1997 to BCS with or without whole-breast RT. Systemic adjuvant treatment was administered according to regional guidelines, but was sparsely used (6% endocrine treatment only, 1% chemotherapy only, and 1% endocrine treatment and chemotherapy). Median follow-up for patients who were included in this study and free from event was 15.2 years, 15.2 years, 20.0 years, and 21.2 years for end points IBTR, any breast cancer recurrence, BCD, and death from any cause, respectively. The trial and follow-up study using tissue microarrays (TMAs) was approved by ethics committees, and oral informed consent was obtained from all patients.
TMA Construction
We collected tumor tissue from formalin-fixed, paraffin-embedded blocks of primary tumors and were able to retrieve tissue from 1,003 of the original 1,178 patients. TMAs were constructed in a semi-automated TMA arrayer (Pathology Devices, Westminster, MD) by extracting two 1.0-mm cylinders from representative tissue.
Staining and Evaluation of Markers
Newly constructed TMA slides were stained for ER (IR084, clone EP1; Dako, Carpinteria, CA), progesterone receptor (PgR; IR068, clone 636; Dako), HER2 (HercepTest; SK308, polyclonal; Dako), and Ki-67 (IR626, clone MIB-1; Dako). TMA slides were pretreated using the Dako PTLink system (Dako) and processed on an automated Dako Autostainer platform. Silver in situ hybridization was performed on Ventana BenchMark Ultra by Ventana INFORM HER2 Dual ISH DNA probe cocktail assay (Ventana Medical Systems, Tucson, AZ). Centralized evaluation was performed by two pathologists who subspecialized in breast pathology who reached consensus. A patient was excluded if any factor was not evaluable. Evaluations were performed on digitally scanned slides (PathXL, Belfast, Northern Ireland). A cutoff of $ 1% was used to consider a tumor ER positive. For PgR, cutoff was $ 20% to distinguish luminal A-like from luminal B-like, and $ 1% to distinguish from triple-negative tumors. HER2 was scored with IHC as 0, 1+, 2+, or 3+, analyzed with silver in situ hybridization, and considered HER2 positive if 3+ and/or amplified. Ki-67 scoring was made according to current guidelines. 32 We used the cutoff proposed by the Swedish Quality and Standardization Committee (KVAST) of having one third of tumors determined Ki-67 high, but adjusted this to a matched regional population, as we assumed that the cohort of stage I and IIA tumors generally have a lower Ki-67 score than the entire breast cancer cohort. This resulted in 27% of tumors being Ki-67 high with a cutoff at 10%. Histologic grade was evaluated as described by Elston and Ellis. 
Statistical Methods
IBTR as the first event within 10 years was used as primary end point. Secondary end points were any breast cancer recurrence within 10 years (IBTR, regional recurrence, or distant recurrence, but not contralateral breast cancer), BCD, and death from any cause. A cumulative incidence and competing risks approach was used for end points IBTR, any recurrence, and BCD. Other recurrences and death were considered competing risks for IBTR, any death considered a competing event for any recurrence, and death from other cause considered a competing risk for BCD. The Kaplan-Meier method was used for death from any cause. To reflect the difference in cumulative incidence functions affected by competing risks, P values for differences between groups (denoted P CIF) were calculated by using a weighted log-rank test as described by Geskus (using the stcrprep command in Stata; Stata, College Station, TX; Computing Resource Center, Santa Monica, CA). 34 Hazard ratios (HRs) were calculated with cause-specific Cox proportional hazards regression to reflect the biologic effect of RT in the presence of competing risks. P values and HRs were calculated up to 10 years for IBTR and any recurrence, otherwise for full follow-up. The proportional hazards assumption was checked graphically and tested with Schoenfeld's test. It was violated (P , .05) for the luminal A-like subtype for end point IBTR and any recurrence, and, thus, the HR must be interpreted as an average over the time studied. Multivariable models with or without an interaction term between subtype and RT were compared to test if the effect of RT differed between subtypes. STATA 14.2 was used for analysis.
RESULTS
Subtyping and Prognostic Value
We were able to stain and score 958 of 1,003 retrieved tumors (Fig 1) . Patient and tumor characteristics for analyzed tumors were similar to those of excluded tumors except for tumor size, where excluded tumors were marginally smaller (median, 11 mm v 12 mm; Fig 1 and Appendix Table A1 , online only). Tumors were classified as luminal A-like (n = 554), luminal B-like (n = 259), triple negative (n = 81), and HER2 positive (ER negative, n = 20; ER positive, n = 44). Patient characteristics divided per subtype and treatment are listed in Table 1 . In the entire cohort, the subtypes were prognostic for any recurrence (P = .02), BCD (P , .001), and death from any cause (P , .001), but not for IBTR at 10 years (P = .7; Appendix Fig A1,  online only) . A difference in time to IBTR was noted with luminal tumors that developed late recurrences, whereas triple-negative and HER2-positive tumors predominantly developed IBTR during the first 5 years ( Table 2 ).
Effect of RT on IBTR as First Event
RT reduced the cumulative incidence of IBTR as the first event after 10 years for luminal A-like tumors (19% v 9%; HR, 0.46; P = .001), luminal B-like tumors (24% v 8%; HR, 0.33; P = .001), and triple-negative tumors (21% v 6%; HR, 0.25; P = .08), but not for HER2-positive tumors (15% v 19%; HR, 1.29; P = .6; Fig 2) . However, an overall difference in RT effect between subtypes could not be demonstrated (P = .21 for interaction). Results were similar after adjustment for prognostic factors (Appendix).
Effect of RT on Any Recurrence, BCD, and Death From Any Cause
RT reduced the cumulative incidence of any recurrence at 10 years for luminal A-like (26% v 14%; HR, 0.50; P , .001), triplenegative tumors (38% v 15%; HR, 0.35; P = .03), and nonsignificantly for luminal B-like tumors (29% v 23%; HR, 0.76; P = .3), but not for HER2-positive tumors (30% v 30%; HR, 1.0; P = 1.0; Fig 2) . RT reduced BCD for triple-negative tumors (HR, 0.35; P = .06), but not for the other tumor subtypes (P = .9, P = .6, and P = .5; Appendix Fig A1) . However, interaction tests for a different effect of RT per subtype on any recurrence and BCD revealed no overall difference (P = .2 and P = .17, respectively). Death from any cause was not decreased by RT in any subtype (Fig 2) .
Low-Risk Group
We previously published that RT reduced the risk of IBTR in a low-risk group (ER positive, N0, age $ 65 years) in this cohort. 13 Here, we sought to evaluate whether subtyping enhances the classification and used the predefined presumed low-risk group of age $ 65 years, N0, and luminal A-like; however, this group did not have a low risk of IBTR, and RT reduced the cumulative incidence of IBTR at 10 years as the first event (20% v 6%; HR, 0.30; P = .008) and the cumulative incidence of any recurrence after 10 years (27% v 9%; HR, 0.30; P = .002), but had no effect on BCD (HR, 0.85; P = .5) or death from any cause (HR, 0.94; P = .7; Fig 3) .
DISCUSSION
In the EBCTCG meta-analysis, all groups defined by traditional clinicopathologic variables demonstrated an effect from RT, although ER-positive tumors had a greater response to RT.
3 Similar differences in response to RT were shown after mastectomy. 35 In contrast, Liu et al 5 recently reported that high-risk tumors have the greatest benefit from RT. Our study is somewhat in line with that of Liu et al as we report that triple-negative tumors (one of the highrisk subtypes) indeed demonstrate an effect from RT. On the contrary, HER2-positive tumors (also a high-risk subtype) do not derive any benefit from RT in our study. Liu et al combine the HER2-positive, basal-like, and triple-negative tumors into a highrisk group, but this high-risk group is arguably heterogeneous, and even within ER-negative tumors, the need for an additional classifier, such as a gene expression test, has been emphasized. 23 Furthermore, in a study that compared response to postmastectomy RT for different subtypes, results were sensitive for how the subtyping was performed and the authors suggested that a subgroup of triple-negative tumors that expressed epidermal growth factor receptor or cytokeratin 5/6 were most radioresistant.
36
Although additional large studies are needed to differentiate subgroups within triple-negative tumors and the luminal versus nonluminal HER2-positive tumors, our study indicates that subgroups of high-risk tumors respond differently to RT and that at least triple-negative and HER2-positive tumors should be analyzed separately. 
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The finding that HER2-positive tumors seem to be more radioresistant should be interpreted with caution, emphasizing the small groups and weak support by the interaction test, and calling for confirmatory studies; however, the radioresistance of HER2-positive tumors-and especially HER2-positive and ERnegative/PgR-negative tumors-was also observed by Kyndi 42 reported HER2-mediated activation of focal adhesion kinase and epithelial-to-mesenchymal transition to confer radioresistance. Indeed, anti-HER2 treatment can be administered under RT and has been shown to be safe, although special attention should be given with regard to cardiotoxicity. [43] [44] [45] The potential enhancement of RT to anti-HER2 treatment should be further investigated.
In contrast to the study by Liu et al, the clinical low-risk luminal A-like group in our study demonstrates an excellent effect from RT on IBTR. An important difference between the studies is the use of adjuvant endocrine therapy, which was used Abbreviations: HER2, human epidermal growth factor receptor 2; IBTR, ipsilateral breast tumor recurrence; RT, radiotherapy. for all patients in the former study, but sparsely in our study and would substantially lower the overall rate of IBTR. The rate of IBTR at 10 years among patients with RT-untreated, low-risk luminal A-like tumors was surprisingly low in the study by Liu et al (1.3% compared with 20% in our study); however, the rate of IBTR among RT-treated patients was almost three-fold higher (5%) in the Liu study, which is more comparable to the 6% among RT-treated patients in our study, but the small groups and BC Recurrence (probability) BC Recurrence (probability) BC Recurrence (probability) BC Recurrence (probability) Death (probability) Death (probability) Death (probability) Death (probability) large CIs should be noted. Another difference between the studies is the exact definition of a low-risk group, and to this end, we also tested to include tumor size , 20 mm and grade 1 and 2 in the definition, which did not alter results (data not shown). Others have shown that tamoxifen and RT decreases the rate of IBTR to a similar extent, or that RT is superior to tamoxifen, and the combination reduces the risk even more. 6-10, 46 As no study has proven the effect on BCD or death from any cause in the low-risk group, some authors argue that the rate of IBTR may be sufficiently low after BCS and endocrine therapy, and that the inconvenience of an IBTR can be weighed against the inconvenience of RT in selected patients.
11,12 Indeed, clinical trials that avoid RT administration to older, low-risk patients are ongoing (eg, the LUMINA study [A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer; ClinicalTrials.gov Identifier: NCT01791829] and the PRIMETIME study 47 [Postoperative Avoidance of Radiotherapy: Biomarker Selection of Women at Very Low Risk of Local Recurrence]). However, our study clearly shows that these patients demonstrate an excellent effect from RT, and perhaps this group could be treated with RT alone given that the risk of distant recurrence is sufficiently low, and whether the patient prefers a treatment that spans 3 to 5 weeks instead of 5 to 10 years, accompanied with adverse effects and an adherence rate of 50% to 80%.
48,49
Subtype has been reported to be prognostic for IBTR [26] [27] [28] [29] ; however, in our study, we observed no direct prognostic effect for IBTR. This could be because we used 10 years as the primary end point, whereas differences between subtypes tend to be largest during the first few years, and most previous prognostic studies have analyzed patients that were administered adjuvant treatment, whereas this study was randomly assigned (1:1) to RT with sparse use of other adjuvant treatment. A different response to adjuvant treatment among subtypes may alter the prognostic effect. Indeed, differences in the rate of IBTR between subtypes is largest in the RT-treated subgroup during the first 5 years and is prognostic at this point (P , .001; Appendix Fig A1) .
A limitation of our study is the power; although it is one of the largest studies of BCS, it was not designed to detect differences in response between subgroups. Whereas we can see indications of variable RT effect on IBTR between subtypes, this could not be statistically confirmed by an interaction test, and confirmatory studies are needed. Another potential limitation is the sparse use of systemic adjuvant treatment, and the absolute effect of RT is likely much smaller with modern treatment.
11,12 Conversely, this provides an opportunity to study the effects of RT alone. Another limitation is that although randomly assigned, the RT-treated and RT-untreated groups are not perfectly balanced in the smallest subtypes (triple negative and HER2 positive). There are differences in age, menopausal status, number of screening-detected tumors, size, and adjuvant treatment that could influence results (Table 1) ; however, a multivariable analysis that adjusted for these factors did not alter the results (Appendix). Furthermore, it is somewhat unexpected that the patients with HER2-positive, RT-untreated tumors had such a favorable prognosis (Fig 1) ; however, the number of HER2-positive patients is low (6.7%), potentially because HER2-positive tumors generally are more aggressive and thus could be under-represented in a N0 trial.
A strength of this study is the centralized pathology, which was made possible by using digitally scanned TMAs, thereby enabling the rapid assessment of thousands of samples by specialized pathologists. Use of TMAs has been shown not to be inferior to whole sections. 50 In previous reports on this trial, ER and PgR status was obtained from patient charts as performed in clinical routine at the time-with a cytosol assay instead of IHC-but was missing in 30% of cases. The new centralized pathology evaluations for ER and PgR presented here have an agreement with the previous assessment of 91% and 88%, respectively. As expected, as the method has become more sensitive and the cutoff has been lowered to 1% for ER-positive status, a shift was observed toward a smaller ER-negative group. The slight difference between the present and previous reports could reflect a better definition of the heterogenous ER-negative and triple-negative group.
In conclusion, subtype was not predictive of response to RT, although in our study HER2-positive tumors seemed to be most radioresistant, whereas triple-negative tumors had the largest effect on BCD. The clinically presumed low-risk, luminal A-like tumors demonstrated an excellent effect from RT with sparse use of systemic therapy, and RT may be an alternative to endocrine therapy in selected cases.
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Time Since Randomly Assigned (years) Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hazard ratio; RT, radiotherapy. *Adjusted for age (linear), tumor size (linear), adjuvant treatment (yes/no), and screening detection (yes/no). †Adjusted for age (linear), tumor size (linear), adjuvant treatment (yes/no), screening detection (yes/no), and also for menopausal status at diagnosis (pre/postmenopausal), and histologic grade 3 (yes/no).
‡Test of interaction between RT and subtype in four groups.
